NCT06525454Completed
Individualized Automatic Target Coaching Message for Glycemic Management and Depressive Symptom
Feasibility and Acceptability of Individualized Automatic Target Coaching Message Based on the Metrics of Continuous Glucose Monitoring and Depressive Symptom
Source: ClinicalTrials.gov · Last updated 13 Nov 2024
Brief summary (registry, in English)
This is a single-center, randomized, prospective, feasibility and acceptability trial in patients with type 1 diabetes. For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires. The control group will remain on their current treatment and will not receive any intervention. The purpose of this trial is to evaluate the feasibility and acceptability of the clinical application of automated, personalized coaching messages for glycemic management and depressive symptom in people with type 1 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 24 Jul 2024
- Start date
- 7 Aug 2024
- Primary completion date
- 18 Sept 2024
- Lead sponsor
- Samsung Medical Center
- Diseases
- Type 1 diabetes
- NCT number
- NCT06525454
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 7 Aug 2024 to the primary completion date, 18 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Steroid and immunosuppressant users
- Subjects receiving anticancer medications
Other
- Subjects using oral hypoglycemic agents
- Breastfeeding or pregnant patients
- Patients who do not voluntarily consent to the study
- Anyone deemed unsuitable by the investigator to participate in the study
Who the study is looking for
- Patients who are determined to use continuous glucose monitoring based on their physician's medical judgment.
- Patients with type 1 diabetes, age 20-69 years old
- Currently receiving treatment with multiple insulin injection therapy
- Patients who have access to KakaoTalk via smartphone and are able to communicate with it
- Voluntarily agreed to participate in this clinical study.
Age in the registry: 20 years to 69 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.